SCHEMBL2239062

SCHEMBL2239062

CCCC(=O)c1ccc(O)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.58
HSP90AB1 P08238 1/20 0.58
HSD17B3 P37058 5/20 0.56
HPGD P15428 5/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 3/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
STS P08842 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
RAB9A P51151 3/20 0.43
CA2 P00918 2/20 0.43
MAPT P10636 2/20 0.43
CA1 P00915 1/20 0.43
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10740496 0.85 HSP90AB1 (0.62) HSP90AA1HSP90AB1HPGDSMN1; SMN2L3MBTL1
SCHEMBL634176 0.85 HSD17B3 (0.55) HSD17B3HPGDSMN1; SMN2L3MBTL1TSHR
SCHEMBL5681582 0.83 HSD17B3 (0.62) HSD17B3HPGDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL11706074 0.82 CA2 (0.51) HSP90AA1HSP90AB1HPGDSMN1; SMN2L3MBTL1
SCHEMBL10034412 0.81 HSD17B3 (0.60) HSD17B3HPGDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL7436605 0.81 HPGD (0.52) HSD17B3HPGDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL11705441 0.80 HSP90AA1 (0.49) HSP90AA1HSP90AB1L3MBTL1ALDH1A1TSHR
SCHEMBL6812061 0.80 HSD17B3 (0.58) HSD17B3HPGDSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL9417188 0.79 ESR1 (0.53) HSP90AA1HSP90AB1HSD17B3HPGDSMN1; SMN2
SCHEMBL2725217 0.79 HSP90AA1 (0.59) HSP90AA1HSP90AB1SMN1; SMN2TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536687-A2 PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES Novartis AG (CH) 2012-12-26 EP disclosed
US-20120302756-A1 PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES NOVARTIS AG (CH) 2012-11-29 US disclosed
WO-2011103263-A2 PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES NOVARTIS AG (CH) 2011-08-25 WO disclosed
CN-1232028-A Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity HOFFMANN LA ROCHE (CH) 1999-10-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302756-A1 PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES DHPS, ALDH18A1, QDPR HSP90AA1 2578/4885HSP90AB1 2732/4885HSD17B3 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.